Moreover, studies have found that BEZ235, an mTOR/PI3K dual inhibitor, was capable of inducing a treatment response and overcoming resistance to everolimus in APC- and PIK3CA-mutant CRC cells [70, 71]. Here, MTOR is linked to colorectal carcinoma.